{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["van Eeghen SA"],"funding":["NCATS NIH HHS","Colorado Clinical and Translational Sciences Institute MicroGrant and CO-Pilot award"],"pagination":["e190850"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12043095"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["135(9)"],"pubmed_abstract":["BACKGROUNDMen with chronic kidney disease (CKD) experience faster kidney function decline than women. Studies in individuals undergoing sex hormone therapy suggest a role for sex hormones, as estimated glomerular filtration rate (eGFR) increases with feminizing therapy and decreases with masculinizing therapy. However, effects on measured GFR (mGFR), glomerular and tubular function, and involved molecular mechanisms remain unexplored.METHODSThis prospective, observational study included individuals initiating feminizing (estradiol and antiandrogens; n = 23) or masculinizing (testosterone; n = 21) therapy. Baseline and 3-month assessments included mGFR (iohexol clearance), kidney perfusion (para-aminohippuric acid clearance), tubular injury biomarkers, and plasma proteomics.RESULTSDuring fe"],"journal":["The Journal of clinical investigation"],"pubmed_title":["Unveiling mechanisms underlying kidney function changes during sex hormone therapy."],"pmcid":["PMC12043095"],"funding_grant_id":["NIH/NCATS TR002535","UL1 TR002535"],"pubmed_authors":["Krebber MM","Vosters TG","van Raalte DH","Obeid W","van Eeghen SA","Pyle L","Parikh CR","Touw DJ","Choi YJ","van Valkengoed IG","Nokoff NJ","Narongkiatikhun P","Bjornstad P","den Heijer M"],"additional_accession":[]},"is_claimable":false,"name":"Unveiling mechanisms underlying kidney function changes during sex hormone therapy.","description":"BACKGROUNDMen with chronic kidney disease (CKD) experience faster kidney function decline than women. Studies in individuals undergoing sex hormone therapy suggest a role for sex hormones, as estimated glomerular filtration rate (eGFR) increases with feminizing therapy and decreases with masculinizing therapy. However, effects on measured GFR (mGFR), glomerular and tubular function, and involved molecular mechanisms remain unexplored.METHODSThis prospective, observational study included individuals initiating feminizing (estradiol and antiandrogens; n = 23) or masculinizing (testosterone; n = 21) therapy. Baseline and 3-month assessments included mGFR (iohexol clearance), kidney perfusion (para-aminohippuric acid clearance), tubular injury biomarkers, and plasma proteomics.RESULTSDuring fe","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-02T07:24:16.426Z","creation":"2025-07-02T03:04:57.698Z"},"accession":"S-EPMC12043095","cross_references":{"pubmed":["40193283"],"doi":["10.1172/JCI190850"]}}